- Home
- HPK vs ARDX Comparison
HPK vs ARDX Comparison
Compare HPK & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | ARDX |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 975.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HPK | ARDX |
|---|---|---|
| Price | $8.03 | $3.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.00 | ★ $15.14 |
| AVG Volume (30 Days) | 417.0K | ★ 3.9M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $863,359,000.00 | $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.85 | $3.33 |
| 52 Week High | $9.13 | $8.40 |
Technical Indicators
Market Signals| Indicator | HPK | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 25.96 |
| Support Level | $7.40 | N/A |
| Resistance Level | $8.49 | $3.92 |
| Average True Range (ATR) | 0.46 | 0.12 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 33.45 | 17.95 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.